Experimental Hematology and Oncology · 2020 · 111 citations · 31 references
Public HealthHealth SciencesOncologyClinical EpidemiologyEpidemiologic MethodsEpidemiologyChronic Disease BurdenDisease BurdenGlobal EpidemiologyLife ExpectancyMortality AnalysisAttributable Disease BurdenBurdenDeath CasesDisability-adjusted Life ExpectancyDisability-adjusted Life Year AnalysisDisability-adjusted Life YearsDisease Burden AnalysisLeukemia Epidemiology
BACKGROUND: Outcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to evaluate the global burden of CML. METHODS: All data used in our study came from the Global Burden of Disease (GBD) study 2017. Incidence cases, death cases, disability-adjusted life-years (DALYs), and its corresponding age-standardized rate between 1990 to 2017 were used to describe the distribution of CML burden, according to age, sex, social-demographic index (SDI), and countries. Data about attributable risk factors contributing to CML deaths and DALYs were also extracted and analyzed. RESULTS: Globally, the disease burden of CML gradually decreased from 1990 to 2017. Higher SDI countries achieved a remarkable effect on diminishing the CML burden. Conversely, due to population growth, the incidence cases, death cases, and DALYs of CML in lower SDI quintiles showed an upward trend. India had the most incidence cases and death cases of CML in the world. Additionally, smoking was the most significant attributable risk factor contributing to CML deaths and DALYs, followed by high body mass index. CONCLUSION: The disease burden of CML decreased globally, especially in higher SDI countries in the past 28 years. The increasing incidence cases and death cases were mainly observed in lower SDI countries. Additionally, strategies to control modifiable risk factors such as smoking and high body mass index might be useful in diminishing mortality and DALYs.
31
Spencer L James, Degu Abate, Kalkidan Hassen Abate et al. · The Lancet · 2018 · 14K citations · Full text
Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate et al. · The Lancet · 2017 · 13.5K citations · Full text
Mohammad H. Forouzanfar, Ashkan Afshin, Lily Alexander et al. · The Lancet · 2016 · 7.8K citations · Full text
Christina Fitzmaurice, Christine A. Allen, Ryan M Barber et al. · JAMA Oncology · 2016 · 6.3K citations · Full text